BridgeBio Pharma has reported new exploratory cardiac findings from the Phase 3 FORTIFY trial suggesting that BBP-418 may affect not only skeletal and respiratory muscle function but also cardiac injury in people with limb-girdle muscular dystrophy type 2I/R9. Among participants who entered the study with elevated high-sensitivity troponin I, all BBP-418-treated patients returned to the normal range by Month 12 compared with 40% receiving placebo, while left ventricular ejection fraction was stable or improved in 54% of treated patients versus 25% of controls. The findings arrive while BBP-418 is already under FDA Priority Review, with a November 27, 2026 target action date.
The new cardiac results are supportive rather than pivotal because the analyses were exploratory, involved relatively small subgroups and were not controlled for multiplicity. They nevertheless broaden the biological picture around BBP-418 after the FORTIFY interim analysis previously met every prespecified primary and secondary endpoint, including measures of motor and pulmonary function. Taken together, the datasets support BridgeBio Pharma’s hypothesis that restoring alpha-dystroglycan glycosylation may modify the underlying disease process across several muscle systems, but the cardiac findings will need continued follow-up before they can be considered evidence of durable cardiomyopathy prevention.
Cardiac biomarkers moved toward normal as BBP-418 targeted another major source of LGMD morbidity
Limb-girdle muscular dystrophy type 2I/R9 is caused by partial loss-of-function mutations in the FKRP gene. Those mutations impair glycosylation of alpha-dystroglycan, a protein involved in maintaining muscle-cell stability, leading over time to progressive skeletal muscle weakness as well as pulmonary and cardiac complications.
Cardiac involvement is particularly important because cardiomyopathy can become a major contributor to morbidity and mortality. BridgeBio Pharma said patients with the common homozygous L276I genotype may develop cardiomyopathy in adulthood, while cardiac involvement can be more frequent in people carrying other FKRP genotypes.
The latest analysis focused in part on high-sensitivity troponin I, a biomarker of myocardial injury. Among participants whose troponin I was elevated at baseline, 100% of those receiving BBP-418 had returned to the normal range by Month 12 compared with 40% in the placebo group. Across the relevant analysis population, the reduction in high-sensitivity troponin I favored BBP-418 by an adjusted mean difference of 17.8 ng/L, with the confidence interval excluding zero.
Left ventricular ejection fraction provided another supportive signal. Fifty-four percent of BBP-418-treated participants had stable or improved ejection fraction at Month 12 compared with 25% of placebo recipients. Because ejection fraction reflects how effectively the heart pumps blood, stabilization could be clinically relevant in a progressive muscular dystrophy where cardiac function may decline over time.
These measurements do not yet establish that BBP-418 prevents cardiomyopathy or improves long-term cardiovascular outcomes. The analyses were exploratory, and BridgeBio Pharma itself cautioned that the small sample sizes and non-alpha-controlled nature of the findings mean they may not predict sustained clinical benefit. The results are therefore best interpreted as mechanistic and supportive evidence alongside the trial’s already positive prespecified endpoints.
Alpha-dystroglycan restoration links the cardiac findings to BBP-418’s proposed mechanism
BBP-418 is an oral substrate intended to increase production of properly glycosylated alpha-dystroglycan despite defective FKRP function. Rather than attempting to replace the mutated gene directly, the therapy is designed to provide additional substrate that helps the residual FKRP enzyme complete a critical biochemical step needed for muscle-cell stability.
BridgeBio Pharma reported that mean glycosylated alpha-dystroglycan levels rose by Month 3 in the FORTIFY trial to levels observed in asymptomatic heterozygous FKRP carriers, who carry one disease-associated variant but do not develop the condition. That restoration was sustained through Month 12.
The biomarker finding matters because it provides evidence that BBP-418 is influencing the molecular defect upstream of the clinical manifestations. If restored alpha-dystroglycan glycosylation translates consistently into improvements in skeletal, respiratory and cardiac muscle function, the therapy could potentially be described as disease modifying rather than simply symptomatic.
The Phase 3 FORTIFY interim analysis previously provided the strongest clinical support for that concept. The study met all prespecified primary and secondary endpoints at 12 months, with BBP-418-treated participants improving while placebo recipients declined across key measures. Earlier separation from placebo was observed on the 100-meter timed test, with ambulatory improvements emerging as early as three months.
BridgeBio Pharma also previously reported a statistically significant and clinically meaningful 2.6-point advantage on the North Star Assessment for Dysferlinopathies-derived functional measure used in the program, together with improvements across additional motor and pulmonary assessments. Those results formed the clinical basis for the company’s New Drug Application and the FDA’s subsequent Priority Review.
FDA review now centers on whether the positive Phase 3 package supports first approval in LGMD
The FDA accepted BridgeBio Pharma’s New Drug Application for BBP-418 and granted Priority Review, assigning a November 27, 2026 target action date. No advisory committee meeting is currently planned.
BBP-418 has also received Fast Track, Orphan Drug and Rare Pediatric Disease designations from the FDA. If approved, BridgeBio Pharma believes it could become the first therapy specifically approved for LGMD2I/R9 and potentially the first approved treatment for any form of limb-girdle muscular dystrophy.
The company estimates that approximately 7,000 people in the United States and Europe live with LGMD2I/R9 or other potentially addressable alpha-dystroglycanopathies. The condition can begin in childhood or early adulthood and progressively impair walking, breathing and cardiac function, creating substantial unmet need for a therapy that acts on the underlying biology.
BridgeBio Pharma is also engaging European regulators regarding a potentially expedited development and approval path. The company plans to begin studies in children younger than 12 years with LGMD2I/R9 during the first half of 2027 and intends to expand development into additional alpha-dystroglycanopathies including LGMD2M/R13 and LGMD2U/R20.
That expansion strategy will depend partly on whether biochemical restoration of glycosylated alpha-dystroglycan produces similar functional benefits across related genetic disorders. A positive FDA decision in LGMD2I/R9 would provide the first regulatory validation of that therapeutic approach.
Exploratory cardiac results add breadth to the evidence but should not be treated as definitive outcomes
The new findings are important because cardiac decline is a clinically meaningful component of LGMD2I/R9 and because FORTIFY had already shown benefits in ambulatory and pulmonary measures. A treatment effect extending across skeletal, respiratory and cardiac muscle would be consistent with correction of a shared underlying muscle-cell defect rather than an isolated improvement in one functional test.
However, the distinction between exploratory and prespecified evidence remains essential. The high-sensitivity troponin I and ejection-fraction analyses were not the primary basis of the trial’s statistical success, and smaller subgroup analyses are more vulnerable to chance findings and baseline imbalances.
Normalization of a cardiac biomarker also does not automatically establish that patients will experience fewer cases of cardiomyopathy, heart failure or other long-term cardiovascular complications. Longer follow-up from FORTIFY and post-approval evidence, if BBP-418 reaches the market, will be needed to determine whether biomarker and ejection-fraction changes translate into durable clinical protection.
The core regulatory case therefore remains the broader Phase 3 dataset that already met its prespecified efficacy objectives. The October cardiac analysis adds biological coherence to that package by suggesting the drug’s impact may extend into another muscle system affected by FKRP deficiency.
With the FDA decision approaching, BBP-418 has moved beyond the question of whether a Phase 3 signal exists. Regulators must now determine whether the totality of functional, pulmonary, biomarker and safety evidence is sufficient to support traditional approval for a disease with no approved targeted therapy.
